Posters

Intravitreal anti-VEGF injections and PCR during cataract surgery

Poster Details

First Author: M.Siddig SUDAN

Co Author(s):                        

Abstract Details

Purpose:

One of the most frequent causes of posterior capsular rupture during cataract surgery in diabetic patients who were injected with Intravitreal Anti-VEGF even if more than 12 months.

Setting:

Catracat and injected with Intravitreal Anti-VEGF.      Diabetic patients who were injected with Intravitreal bevacizumab (Avastin, Losantos ,.... ) between 2015 to 2018. Those patients were divided into four groups (250 patients for each group). Those patients were from different eye hospitals.

Methods:

Those patients were divided into four groups (250 pt each group). The distribution of groups was as follows: The first group: diabetic patients who have been developed cataract regardless of the duration of the disease, they were underwent cataract surgery . The second group: diabetic patients who need cataract surgery and at the same time injection of Anti-VEGF The third group: diabetic patients with cataract who were injected with intravitreal Anti-VEGF, the last of which was +/- 11 months ago The fourth group: diabetic patients with cataract whi were injected with Anti-VEGEF medication more than 12 months

Results:

In this study, there were 80 patients who encountered rupture of the posterior capsule during catracat surgery. 90% of these patients were in the fourth group, 10% were from the third group. No case was recorded within the first or second groups. In fact, during this research I couldn't find a standard device to measure the thickness of the posterior lens capsule .but the Femtosecond laser which gives different measurement in Non-diabetic patients than in the diabetic patients who were injected with intravitreal Anti-VEG medications. From this notice, we pose the following question; do the Anti-VEGF drugs affect the posterior lens capsule?

Conclusions:

It is better for us to deal with all patients as we dealt with the second group, which is referred to in the study, we also dealt with each of the last two groups as we saw from the results of the study. This study shows us that the intravitreal Anti-VEFG medications have a very impressive effect on diabetic retinopathy but the posterior capsule is influenced negatively by them. Thus, during cataract surgery in diabetic patients who have been injected with intravitreal Anti-VEGF drugs even if for more than 11 months, the posterior lens capsule should be handled very cautiously.

Financial Disclosure:

None